Shanghai Siqiang Biotechnology

Siqiang Biotech is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development of mRNA therapeutics and vaccines. The company's core strength lies in its proprietary lipid nanoparticle (LNP) delivery technology, which features a diverse library of ionizable lipids designed for high efficiency and low toxicity. Siqiang Biotech's pipeline includes a COVID-19 mRNA vaccine candidate and several preclinical programs targeting infectious diseases and cancer. By integrating sequence design, LNP formulation, and manufacturing capabilities, the company seeks to accelerate the translation of nucleic acid medicines.